论文部分内容阅读
Glioma,as the most common and aggressive malignant central nervous system(CNS)tumor with generally poor prognosis,has been attracting much attention in the last decade[1].Temozolomide was firstly available in the United States in1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma.The World
Glioma, as the most common and aggressive malignant central nervous system (CNS) tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was initially available in the United States in 1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma.The World